Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04958226 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Effect of Capivasertib on Midazolam in Patients With Advanced Solid Tumours
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
NCT04958226 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 21 participants.
The verdict
NCT04958226, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
This is an open-label, fixed-sequence study to evaluate the effect of capivasertib on the pharmacokinetics (PK) of midazolam, a sensitive CYP3A substrate. The PK of midazolam will be assessed when administered alone and in combination with repeated doses of capivasertib.
Interventions
- DRUG Midazolam
- DRUG Capivasertib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2021-10-15 |
| Est. Completion | 2023-02-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04958226
The ClinicalTrials.gov registry entry for NCT04958226 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Midazolam is the first listed.
NCT04958226 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04958226 about?
NCT04958226 is a clinical study titled "A Study to Assess the Effect of Capivasertib on Midazolam in Patients With Advanced Solid Tumours". This is an open-label, fixed-sequence study to evaluate the effect of capivasertib on the pharmacokinetics (PK) of midazolam, a sensitive CYP3A substrate. The PK of midazolam will be assessed when administered alone and in combination with repeated doses of capivasertib.
What is the current status of trial NCT04958226?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2021-10-15. Estimated completion is 2023-02-15.
What interventions are being tested in trial NCT04958226?
The interventions under investigation include: Midazolam (DRUG), Capivasertib (DRUG).
Who is sponsoring clinical trial NCT04958226?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.